Imaging and Endo-vascular Treatment of Extra-hepatic Portal Vein Obstruction

Monday, March 6, 2023

1:00 PM – 2:30 PM

Location:Phoenix Convention Center, 232AB

CE: 1.5 Credits

Coordinator(s)

Sanjeeva Kalva, MD, FSIR, FCIRSE, FACR (he/him/his)

Professor
Massachusetts General Hospital

Disclosure(s): BD Bard: Consultant (Ongoing); Biogen Inc, Clover Health Investments Corp, Inovio Pharmaceuticals, Moderna Inc, Pfizer Inc, Novavax Inc, Orphazyme, Cassava Sciences Inc, Vivos Therapeutics Inc, Ardelyx Inc, Althea Health, Sarepta Therapeutics, Clover Health Investments Corp, CureV: Ownership Interest (Ongoing), Stocks (Ongoing); Boston Scientific Corp: Consultant (Ongoing); Canon Medical: Consultant (Ongoing), Speaking and Teaching (Ongoing); Covidien/Medtronic: Consultant (Ongoing); Instylla, Inc.: Consultant (Ongoing); Okami Medical: Consultant (Ongoing); Penumbra Inc.: Consultant (Terminated), Speaking and Teaching (Terminated); Sirtex Medical: Consultant (Ongoing); Varian: Consultant (Ongoing)
GH

Gloria Hwang, MD, FSIR

Clinical Associate Professor
Stanford University Medical Center

Disclosure(s): No financial relationships to disclose

Disclosure(s):

Sanjeeva Kalva, MD, FSIR, FCIRSE, FACR: BD Bard: Consultant (Ongoing); Biogen Inc, Clover Health Investments Corp, Inovio Pharmaceuticals, Moderna Inc, Pfizer Inc, Novavax Inc, Orphazyme, Cassava Sciences Inc, Vivos Therapeutics Inc, Ardelyx Inc, Althea Health, Sarepta Therapeutics, Clover Health Investments Corp, CureV: Ownership Interest (Ongoing), Stocks (Ongoing); Boston Scientific Corp: Consultant (Ongoing); Canon Medical: Consultant (Ongoing), Speaking and Teaching (Ongoing); Covidien/Medtronic: Consultant (Ongoing); Instylla, Inc.: Consultant (Ongoing); Okami Medical: Consultant (Ongoing); Penumbra Inc.: Consultant (Terminated), Speaking and Teaching (Terminated); Sirtex Medical: Consultant (Ongoing); Varian: Consultant (Ongoing)

Gloria Hwang, MD, FSIR: No financial relationships to disclose

This case-based discussion reviews imaging, intra-procedural tools and endovascular treatment options of extra-hepatic portal vein obstruction. The treatments that would discussed include portal vein recanalization, DIPS/TIPS, portal/mesenteric/splenic vein stenting, splenic embolization and extra-anatomical bypass (percutaneous splenorenal shunt).

Learning Objectives:

Discuss CT arterioportography in the pre-operative evaluation of patient with EHPVO
Discuss options and endovascular methods of treatment for EHPVO
Review follow up following endovascular therapy for EHPVO

Presentations:

1:00 PM – 1:15 PM

Imaging and Intra-procedural imaging tools for interventions for Extrahepatic portal vein obstruction
Speaker: Sanjeeva Kalva, MD, FSIR, FCIRSE, FACR (he/him/his) – Massachusetts General Hospital
1:15 PM – 1:30 PM

Splenic embolization
Speaker: Gloria Hwang, MD, FSIR – Stanford University Medical Center
1:30 PM – 1:45 PM

TIPS/DIPS, Extra-anatomical bypass and ancillary interventions for Extra-hepatic portal vein obstruction
Speaker: Sundeep Punamiya, MD, FSIR, FAMS – Tan Tock Seng Hospital
1:45 PM – 2:00 PM

Portal Vein Recanalization for Extra-hepatic portal vein obstruction
Speaker: Bartley Thornburg, MD – Northwestern Memorial Hospital
2:00 PM – 2:15 PM

Porto-mesenteric venous stenting
Speaker: Joshua Kuban, MD – University of Texas MD Anderson Cancer Center
2:15 PM – 2:30 PM

Q & A